Skip to content

uniQure QURE Total Equity

Total Equity at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$236M-264%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$926.1M-17.5%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$180.47M+2.9%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$1.81B-0.8%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$1.28B+29.7%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$2.28B-38.2%

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's total equity?
uniQure (QURE) reported total equity of $149.34M in Q1 2026.
How has uniQure's total equity changed year-over-year?
uniQure's total equity increased by 343.3% year-over-year, from $33.69M to $149.34M.
What is the long-term trend for uniQure's total equity?
Over 5 years (2020 to 2025), uniQure's total equity has grown at a -4.0% compound annual growth rate (CAGR), from $243.91M to $198.9M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.